JP2018503696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503696A5 JP2018503696A5 JP2017559275A JP2017559275A JP2018503696A5 JP 2018503696 A5 JP2018503696 A5 JP 2018503696A5 JP 2017559275 A JP2017559275 A JP 2017559275A JP 2017559275 A JP2017559275 A JP 2017559275A JP 2018503696 A5 JP2018503696 A5 JP 2018503696A5
- Authority
- JP
- Japan
- Prior art keywords
- minutes
- mtorr
- product
- composition
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 123
- 238000000034 method Methods 0.000 claims description 102
- 239000000843 powder Substances 0.000 claims description 71
- 239000008194 pharmaceutical composition Substances 0.000 claims description 70
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 67
- 238000010438 heat treatment Methods 0.000 claims description 64
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 56
- 238000013019 agitation Methods 0.000 claims description 51
- 238000001035 drying Methods 0.000 claims description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
- 229910052785 arsenic Inorganic materials 0.000 claims description 40
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 37
- 239000002253 acid Substances 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 239000004094 surface-active agent Substances 0.000 claims description 29
- 230000003113 alkalizing effect Effects 0.000 claims description 27
- 239000003125 aqueous solvent Substances 0.000 claims description 22
- 238000007710 freezing Methods 0.000 claims description 21
- 230000008014 freezing Effects 0.000 claims description 21
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims description 19
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 19
- 239000002775 capsule Substances 0.000 claims description 17
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 16
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 15
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 14
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 230000003381 solubilizing effect Effects 0.000 claims description 14
- 239000000945 filler Substances 0.000 claims description 13
- 239000000314 lubricant Substances 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 9
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 239000001116 FEMA 4028 Substances 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 claims description 7
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 7
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 7
- 229960004853 betadex Drugs 0.000 claims description 7
- 238000012792 lyophilization process Methods 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 229960000502 poloxamer Drugs 0.000 claims description 7
- 229920001983 poloxamer Polymers 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 7
- 239000000454 talc Substances 0.000 claims description 7
- 229910052623 talc Inorganic materials 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000007452 Plasmacytoma Diseases 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 2
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 2
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000006894 monocytic leukemia Diseases 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 2
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 2
- 208000037244 polycythemia vera Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000002784 sclerotic effect Effects 0.000 claims description 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 2
- 238000007873 sieving Methods 0.000 claims 2
- 239000013020 final formulation Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021103196A JP7539855B2 (ja) | 2015-02-01 | 2021-06-22 | 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物 |
| JP2024135193A JP2024161468A (ja) | 2015-02-01 | 2024-08-14 | 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110574P | 2015-02-01 | 2015-02-01 | |
| US62/110,574 | 2015-02-01 | ||
| US201562142709P | 2015-04-03 | 2015-04-03 | |
| US62/142,709 | 2015-04-03 | ||
| PCT/US2016/015917 WO2016123603A2 (en) | 2015-02-01 | 2016-02-01 | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103196A Division JP7539855B2 (ja) | 2015-02-01 | 2021-06-22 | 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503696A JP2018503696A (ja) | 2018-02-08 |
| JP2018503696A5 true JP2018503696A5 (enExample) | 2019-03-14 |
| JP6928768B2 JP6928768B2 (ja) | 2021-09-01 |
Family
ID=56544541
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017559275A Active JP6928768B2 (ja) | 2015-02-01 | 2016-02-01 | 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物 |
| JP2021103196A Active JP7539855B2 (ja) | 2015-02-01 | 2021-06-22 | 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物 |
| JP2024135193A Pending JP2024161468A (ja) | 2015-02-01 | 2024-08-14 | 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103196A Active JP7539855B2 (ja) | 2015-02-01 | 2021-06-22 | 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物 |
| JP2024135193A Pending JP2024161468A (ja) | 2015-02-01 | 2024-08-14 | 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10111836B2 (enExample) |
| EP (3) | EP4599823A1 (enExample) |
| JP (3) | JP6928768B2 (enExample) |
| CN (2) | CN117899029A (enExample) |
| AU (4) | AU2016211186A1 (enExample) |
| CA (2) | CA3225480A1 (enExample) |
| DK (1) | DK3981414T3 (enExample) |
| ES (2) | ES3034734T3 (enExample) |
| FI (1) | FI3981414T3 (enExample) |
| HR (1) | HRP20251032T1 (enExample) |
| HU (1) | HUE072537T2 (enExample) |
| LT (1) | LT3981414T (enExample) |
| MX (2) | MX390835B (enExample) |
| PL (1) | PL3981414T3 (enExample) |
| PT (1) | PT3981414T (enExample) |
| RS (1) | RS67133B1 (enExample) |
| SI (1) | SI3981414T1 (enExample) |
| SM (1) | SMT202500321T1 (enExample) |
| TW (3) | TWI790191B (enExample) |
| WO (1) | WO2016123603A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202500321T1 (it) | 2015-02-01 | 2025-11-10 | Quetzal Therapeutics Llc | Composizioni liofilizzate ad area superficiale elevata comprendenti arsenico per la somministrazione orale a pazienti |
| IL265986B (en) | 2016-12-01 | 2022-09-01 | Eupharma Pty Ltd | Pharmaceutical composition comprising an alkali metal and/or an alkaline earth metal diarsenic (iii) tetraoxide and uses thereof |
| KR101844049B1 (ko) | 2016-12-05 | 2018-03-30 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물 |
| KR101844050B1 (ko) | 2016-12-09 | 2018-05-14 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물 |
| US20190374611A1 (en) * | 2017-01-18 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders |
| US11583552B2 (en) * | 2021-02-17 | 2023-02-21 | Manoj Maniar | Pharmaceutical formulation of arsenic trioxide |
| JP7428842B1 (ja) | 2023-03-29 | 2024-02-06 | ａｒｔｉｅｎｃｅ株式会社 | 活性エネルギー線硬化型インキ、その製造方法、および印刷物 |
| WO2025172482A1 (en) | 2024-02-14 | 2025-08-21 | Institut Gustave Roussy | Oral composition of arsenic trioxide for cancer treatment |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773419A (en) | 1995-03-03 | 1998-06-30 | Falcon; Juan | Method of treating cancer with tannic acid |
| CN1044559C (zh) | 1995-08-23 | 1999-08-11 | 哈尔滨医科大学附属第一医院 | 抗白血病、肝癌、淋巴瘤注射液 |
| JP2001522799A (ja) * | 1997-11-10 | 2001-11-20 | メモリアル スローン−ケタリング キャンサー センター | 三酸化ヒ素製剤の製造方法および三酸化ヒ素またはメラルソプロールを使用する癌の治療方法 |
| US7276359B1 (en) * | 1998-03-13 | 2007-10-02 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
| CN1131922C (zh) | 1998-10-19 | 2003-12-24 | 张在喆 | 一种通过弹性键搭架与收拢的帐篷 |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| CN1310999A (zh) * | 2000-02-29 | 2001-09-05 | 布里斯托尔-迈尔斯斯奎布公司 | 低剂量艾替开韦制剂及其应用 |
| AUPR874601A0 (en) * | 2001-11-08 | 2001-11-29 | Unisearch Limited | Selective targeting of apoptotic cells |
| US8906422B2 (en) | 2002-10-09 | 2014-12-09 | The University Of Hong Kong | Method for inhibiting cancer using arsenic trioxide |
| US7521071B2 (en) | 2002-10-09 | 2009-04-21 | Versitech Limited | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| GB0315632D0 (en) * | 2003-07-04 | 2003-08-13 | West Pharm Serv Drug Res Ltd | Pharmaceutical formulations |
| CN1251688C (zh) | 2003-12-09 | 2006-04-19 | 重庆维特瑞医药开发有限公司 | 三氧化二砷冻干粉针及其生产方法 |
| JP4292985B2 (ja) | 2003-12-25 | 2009-07-08 | Ｊｓｒ株式会社 | 感放射線性組成物、マイクロレンズとその形成方法および液晶表示素子 |
| CN1698650A (zh) | 2004-05-21 | 2005-11-23 | 哈尔滨伊达药业有限公司 | 一种治疗原发性肝癌的亚砷酸注射液及其制备方法 |
| CN1326528C (zh) | 2004-07-13 | 2007-07-18 | 东南大学 | 砒霜磁性纳米明胶微球的制备工艺 |
| WO2007069272A2 (en) | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| US20080089951A1 (en) * | 2006-10-11 | 2008-04-17 | The University Of Hong Kong | Method for Inhibiting Cancer Using Arsenic Trioxide |
| CN101322719B (zh) * | 2007-06-15 | 2012-03-07 | 杭州民生药业有限公司 | 一种三氧化二砷固体脂质纳米粒及其制剂 |
| US8168224B2 (en) * | 2007-12-19 | 2012-05-01 | Beijing Shengyiyao Science & Technology Development Co., Ltd. | Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof |
| MX2011002847A (es) | 2008-09-19 | 2011-04-07 | Activus Pharma Co Ltd | Polvo de compuesto organico combinado para uso medico y metodo de produccion y suspension del mismo. |
| EP2525783A1 (en) | 2010-01-18 | 2012-11-28 | Cephalon France | Improved oral lysophilisates containing pvp/va |
| EP2359812A1 (en) | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
| CN103142648B (zh) * | 2011-12-07 | 2015-04-15 | 浙江中医药大学 | 一种砷化合物溶液及其制备的包载砷化合物的白蛋白纳米粒和冻干制剂 |
| CN103408477B (zh) | 2013-08-22 | 2015-06-10 | 陈鹏飞 | 一种含砷配位化合物及其制备方法 |
| DK3250213T3 (en) | 2015-01-29 | 2023-09-11 | Eupharma Pty Ltd | Compositions containing arsenic for use in methods of treatment |
| SMT202500321T1 (it) | 2015-02-01 | 2025-11-10 | Quetzal Therapeutics Llc | Composizioni liofilizzate ad area superficiale elevata comprendenti arsenico per la somministrazione orale a pazienti |
-
2016
- 2016-02-01 SM SM20250321T patent/SMT202500321T1/it unknown
- 2016-02-01 CA CA3225480A patent/CA3225480A1/en active Pending
- 2016-02-01 AU AU2016211186A patent/AU2016211186A1/en not_active Abandoned
- 2016-02-01 ES ES21192594T patent/ES3034734T3/es active Active
- 2016-02-01 TW TW105103175A patent/TWI790191B/zh active
- 2016-02-01 PT PT211925946T patent/PT3981414T/pt unknown
- 2016-02-01 PL PL21192594.6T patent/PL3981414T3/pl unknown
- 2016-02-01 EP EP25184422.1A patent/EP4599823A1/en active Pending
- 2016-02-01 TW TW111149127A patent/TW202337477A/zh unknown
- 2016-02-01 CN CN202311663020.2A patent/CN117899029A/zh active Pending
- 2016-02-01 ES ES16744263T patent/ES2899226T3/es active Active
- 2016-02-01 LT LTEP21192594.6T patent/LT3981414T/lt unknown
- 2016-02-01 WO PCT/US2016/015917 patent/WO2016123603A2/en not_active Ceased
- 2016-02-01 CA CA2975406A patent/CA2975406C/en active Active
- 2016-02-01 US US15/012,355 patent/US10111836B2/en active Active
- 2016-02-01 FI FIEP21192594.6T patent/FI3981414T3/fi active
- 2016-02-01 DK DK21192594.6T patent/DK3981414T3/da active
- 2016-02-01 RS RS20250815A patent/RS67133B1/sr unknown
- 2016-02-01 MX MX2017009913A patent/MX390835B/es unknown
- 2016-02-01 EP EP21192594.6A patent/EP3981414B1/en active Active
- 2016-02-01 HR HRP20251032TT patent/HRP20251032T1/hr unknown
- 2016-02-01 JP JP2017559275A patent/JP6928768B2/ja active Active
- 2016-02-01 TW TW110142380A patent/TW202228734A/zh unknown
- 2016-02-01 SI SI201631917T patent/SI3981414T1/sl unknown
- 2016-02-01 CN CN201680020478.8A patent/CN107530373B/zh active Active
- 2016-02-01 EP EP16744263.1A patent/EP3250214B1/en active Active
- 2016-02-01 HU HUE21192594A patent/HUE072537T2/hu unknown
-
2017
- 2017-07-31 MX MX2020012611A patent/MX2020012611A/es unknown
-
2018
- 2018-10-01 US US16/148,193 patent/US10272045B2/en active Active
-
2019
- 2019-03-12 US US16/299,214 patent/US10653628B2/en active Active
-
2020
- 2020-04-20 US US16/852,758 patent/US20210069115A1/en not_active Abandoned
-
2021
- 2021-06-07 AU AU2021203752A patent/AU2021203752B2/en active Active
- 2021-06-22 JP JP2021103196A patent/JP7539855B2/ja active Active
-
2023
- 2023-01-27 US US18/160,445 patent/US12364664B2/en active Active
- 2023-08-10 AU AU2023214307A patent/AU2023214307B2/en active Active
-
2024
- 2024-01-10 US US18/408,664 patent/US20240269076A1/en active Pending
- 2024-08-14 JP JP2024135193A patent/JP2024161468A/ja active Pending
-
2025
- 2025-10-29 AU AU2025259861A patent/AU2025259861A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503696A5 (enExample) | ||
| JP2022141701A (ja) | ブルトン型チロシンキナーゼ阻害剤の薬学的製剤 | |
| JP2020535158A (ja) | ニラパリブ処方物 | |
| FI3981414T3 (fi) | Suuren pinta-alan kylmäkuivattuja, arseenia käsittäviä, potilaille suun kautta annettavia koostumuksia | |
| TW202042808A (zh) | 二種抗病毒化合物之組合調合物 | |
| JP6126456B2 (ja) | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 | |
| CN101511343A (zh) | 使用多元醇来获得利福昔明的稳定的多晶型形式 | |
| TWI700100B (zh) | 用於口服投藥之包含依澤替米貝（ｅｚｅｔｉｍｉｂｅ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）的複合調配物及其製備方法 | |
| CN105232488A (zh) | 一种含有利伐沙班的固体药物组合物 | |
| CN101439030A (zh) | 一种含番茄红素的药物组合物及其制备方法 | |
| CN108430460A (zh) | 包含度他雄胺和丙二醇单月桂酸酯的药物组合物及其制备方法 | |
| TW201322979A (zh) | 醫藥組成物 | |
| JP7674080B2 (ja) | アビラテロン酢酸エステル含有製剤 | |
| ES2881883T3 (es) | Composiciones farmacéuticas que comprenden derivado de fenilaminopirimidina | |
| CN119421703A (zh) | 无定形固体分散体和包含所述无定形固体分散体的药物组合物 | |
| JP2017516792A (ja) | 経口イソトレチノイン医薬組成物 | |
| CN104146978A (zh) | 一种双硫仑肠溶片剂及其制备方法 | |
| JP2017523149A (ja) | エドキサバンの医薬組成物 | |
| CN102137664B (zh) | 具有被边界隔开的有效成分的固体药物制剂 | |
| KR20200117998A (ko) | 약학적 조성물 | |
| TWI586379B (zh) | 一種製作難溶藥物固體劑型的方法 | |
| JP7640453B2 (ja) | 医薬製剤およびその製造方法 | |
| CN102675338A (zh) | 微粉化普拉格雷及其药用组合物 | |
| ES2734675T3 (es) | Formulación de comprimido dispersable en agua que contiene deferasirox | |
| JP5680607B2 (ja) | 安定固形製剤及びその製造法 |